New York patients on long-term opioids who used medical cannabis for a month were twice as likely to quit them

Researchers pulled records from New York's Medical Cannabis Program and its prescription monitoring system for 8,358 adults on long-term opioid therapy for chronic pain who had also obtained medical cannabis between 2017 and 2019. They followed each patient for 90 days and counted a gap of at least 45 days without an opioid prescription as discontinuation.

Among the 4,892 patients who used medical cannabis for more than 30 days, 15.5 percent stopped opioids, against 7.6 percent of the 3,466 who used it for 30 days or less. The gap shrank by dose. In the under-50 morphine milligram equivalent group, longer use meant discontinuation was roughly 1.8 to 2.9 times more likely. In the 50 to under 90 group it was about 3.1 times more likely. At 90 MME or more, there was no statistically significant association.

The limits matter. This is observational data, so it cannot show cannabis caused anyone to quit. The records do not say whether pain improved, and they do not show whether patients stopped under a doctor's supervision, which is a safety question for anyone dependent on opioids.

Takeaway for dispensaries and patients: the finding fits a growing body of work linking cannabis to lower opioid use, but it is not a treatment claim. Anyone cutting opioid doses should do it with a prescriber, and shops should not market this as a substitute for medical care.